Longitudinal outcomes with cancer multigene panel testing in previously tested BRCA1/2 negative patients.
cancer genetic testing
cancer prevention and screening
delivery of genetic services
genetic testing outcomes
multigene panel testing
Journal
Clinical genetics
ISSN: 1399-0004
Titre abrégé: Clin Genet
Pays: Denmark
ID NLM: 0253664
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
07
10
2019
revised:
07
01
2020
accepted:
23
01
2020
pubmed:
6
2
2020
medline:
4
6
2021
entrez:
6
2
2020
Statut:
ppublish
Résumé
Although multigene panel testing (MGPT) is increasingly utilized in clinical practice, there remain limited data on patient-reported outcomes. BRCA 1/2 negative patients were contacted and offered MGPT. Patients completed pre- and posttest counseling, and surveys assessing cognitive, affective and behavioral outcomes at baseline, postdisclosure and 6 and 12 months. Of 317 eligible BRCA1/2 negative patients who discussed the study with research staff, 249 (79%) enrolled. Decliners were more likely to be older, non-White, and recruited by mail or email. Ninety-five percent of enrolled patients proceeded with MGPT. There were no significant changes in anxiety, depression, cancer specific distress or uncertainty postdisclosure. There were significant but small increases in knowledge, cancer-specific distress and depression at 6-12 months. Uncertainty declined over time. Those with a VUS had significant decreases in uncertainty but also small increases in cancer specific distress at 6 and 12 months. Among those with a positive result, medical management recommendations changed in 26% of cases and 2.6% of all tested. Most BRCA1/2 negative patients have favorable psychosocial outcomes after receipt of MGPT results, although small increases in depression and cancer-specific worry may exist and may vary by result. Medical management changed in few patients.
Identifiants
pubmed: 32022897
doi: 10.1111/cge.13716
pmc: PMC9984207
mid: NIHMS1877662
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
BRCA2 Protein
0
BRCA2 protein, human
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
601-609Subventions
Organisme : NCI NIH HHS
ID : P30 CA006927
Pays : United States
Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Genet Med. 2014 Nov;16(11):830-7
pubmed: 24763289
JAMA Oncol. 2015 Oct;1(7):943-51
pubmed: 26270727
JAMA Oncol. 2017 Apr 01;3(4):464-471
pubmed: 27978560
JCO Precis Oncol. 2018;2:
pubmed: 31819920
BMC Public Health. 2017 May 25;17(1):503
pubmed: 28545429
Patient Educ Couns. 2013 Dec;93(3):413-9
pubmed: 24075727
Genet Med. 2016 Jan;18(1):25-33
pubmed: 25834950
Genet Med. 2012 Jul;14(7):681-7
pubmed: 22481132
Clin Colorectal Cancer. 2018 Jun;17(2):e293-e305
pubmed: 29454559
Oncology (Williston Park). 2016 Sep 15;30(9):800, 807
pubmed: 27633410
JCO Precis Oncol. 2018;2018:
pubmed: 30656245
Cancer Control. 2004 Jul-Aug;11(4):236-44
pubmed: 15284715
J Genet Couns. 2006 Oct;15(5):325-37
pubmed: 16972194
JAMA Oncol. 2015 Jun;1(3):277-8
pubmed: 26181167
J Genet Couns. 2007 Feb;16(1):85-96
pubmed: 17295054
Clin Genet. 2015 Sep;88(3):278-82
pubmed: 25318351
Health Psychol. 2009 Jul;28(4):510-8
pubmed: 19594276
J Psychosom Res. 2002 Feb;52(2):69-77
pubmed: 11832252
Health Psychol. 2002 Nov;21(6):564-72
pubmed: 12433008
JAMA Oncol. 2018 Aug 1;4(8):1066-1072
pubmed: 29801090
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Acta Oncol. 2018 Jan;57(1):159-162
pubmed: 29168416
Eur J Hum Genet. 2014 Jul;22(7):866-74
pubmed: 24253862
JMIR Res Protoc. 2014 Oct 29;3(4):e49
pubmed: 25355401
Psychosom Med. 1979 May;41(3):209-18
pubmed: 472086
J Clin Oncol. 2017 Jul 10;35(20):2232-2239
pubmed: 28402748
Genet Med. 2015 Jun;17(6):485-92
pubmed: 25297947
JCO Precis Oncol. 2018;2:
pubmed: 32095738
J Genet Couns. 2017 Oct;26(5):1116-1129
pubmed: 28357778
J Natl Cancer Inst. 2018 Aug 1;110(8):797-798
pubmed: 29529278
J Natl Cancer Inst. 2018 Sep 1;110(9):985-993
pubmed: 29490071
JAMA. 1996 Jun 26;275(24):1885-92
pubmed: 8648868
Genet Med. 2015 Feb;17(2):97-8
pubmed: 25032987
J Community Genet. 2018 Jan;9(1):81-92
pubmed: 28971318
Genet Med. 2018 Nov;20(11):1324-1327
pubmed: 29493579
J Clin Oncol. 2015 Nov 1;33(31):3660-7
pubmed: 26324357